Partners Group Private Equity Limited

The net asset value of Partners Group Private Equity fell by 0.7% in May to €11.84 per share, corresponding to total assets of €801.71m. The decline resulted mainly from portfolio revaluations, partially offset by a positive currency effect of 0.2%. The main driver was a writedown of real estate services provider Emeria due to weaker operational performance and a reduced valuation multiple; Emeria reportedly has no liquidity problems and continues to receive support. Newer investments such as Rosen Group and MPM Products, the company says, are showing positive early operational momentum; PGPE had €68.8m in liquidity at the end of May plus an undrawn credit line of €150.0m. » More on de.investing.com

Partners Group Private Equity reports a 2.5% decline in net asset value in April to 12.26 EUR per share, driven by portfolio revaluations of -1.8% and negative currency effects of -0.7%. Two investments were major contributors to the decline: Pharmathen was fully written down after an FDA import warning, and United States Infrastructure Corporation was downgraded due to insourcing and operational problems. During the reporting month the company received distributions of 23.9 million EUR, mainly from the sale of Clario to Thermo Fisher, and announced an additional allocation of 18 million EUR for its buyback program. The board approved an interim dividend of 0.325 EUR per share (22.1 million EUR), payable on 19 June 2026. » More on de.investing.com

Partners Group Private Equity has approved a buyback program of €18m after reporting free cash flow of €24m as of 31 March 2026. The allocation was made because the shares are trading at a discount of 30% or more to net asset value. In addition, €1.6m of unused capital from an October 2025 program is being added, bringing the combined buyback volume to €19.6m, which runs until 31 July 2026. For the quarter the company reported committed distributions of around €56m and investment activity of about €12m. » More on de.investing.com